DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Oprah Winfrey - 1 Eli Lilly - 1 they've - 1 Lilly's - 1 Lilly's Zepbound - 1 Andy Acker - 1 Janus Henderson's - 1 Lilly - 1
Top related locs:
Friday's Eccogene MedTech 3Q23
Top related orgs:
Novo Nordisk - 1 Wall Street - 1 Wall - 1 RBC Capital - 1 Pfizer - 1 Structure Therapeutics - 1 AstraZeneca - 1 Leerink - 1

Search resuls for: "Andy Acker"


2 mentions found


☆ Oprah's flip on weight loss drugs is a sign of what's to come for the 'Ozempic trade' in 2024
  + stars: | 2023-12-25 | by ( Christina Cheddar Berk | In | ) www.cnbc.com   time to read: +10 min
Lilly's Zepbound recently entered the weight loss market, and is off to a strong start. But what's ahead for the weight loss trade in 2024? Beyond weight loss One of 2023's most pivotal events in the space was Novo Nordisk's release of top line results from its Select trial in August . In 2023, the exuberance around weight loss drugs roiled markets in many unexpected ways. The affected companies have also been very vocal in addressing how they plan to coexist with these weight loss products.
Persons: Oprah Winfrey, Eli Lilly, they've, Lilly's, Lilly's Zepbound, Andy Acker, Janus Henderson's, Lilly, Novo, FactSet, Acker, Janus, Buzz, Gregory Renza, Renza, Goldman Sachs, Chris Shibutani, Mike Kratky, Kratky, Dexcom, Leerink, Winfrey, I've, Winfrey's, Michael Bloom Organizations: Novo Nordisk, Wall Street, Wall, RBC Capital, Pfizer, Structure Therapeutics, AstraZeneca, Leerink, Nestle, Oprah Daily, Winfrey, International Locations: Friday's, Eccogene, MedTech, 3Q23
☆ ASCO conference will put the focus on the fight against cancer. These stocks are in the spotlight
  + stars: | 2023-05-28 | by ( Christina Cheddar Berk | ) www.cnbc.com   time to read: +9 min
Developments in cancer research will be in the spotlight as the American Society of Clinical Oncology hosts the world's biggest cancer research conference in Chicago, starting Thursday. The pair has already has won regulatory approval for Enhertu for metastatic HER2-low breast cancer, but the companies are also studying its use in a variety other HER2 tumors in breast cancers. Lilly's drug, Verzenio, is used in high-risk patients with HR-positive HER2-negative breast cancer that is more likely to reoccur and has already breached the patient's lymph nodes. In a research note earlier this month, Guggenheim analyst Seamus Fernandez said Kisqali is already taking market share from Pfizer's Ibrance in metastatic breast cancer. Merck's Keytruda is also being watched for what benefits it could offer early-stage lung cancer patients .
0 next >>
Total: 2